Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 1:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ctDNA Clear all
Completed No phase listed Observational

Changes in Circulating Tumor-Specific DNA in Patients With Non-Metastatic Non-Small Cell Lung Cancer

NCT03746262
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 20, 2018 · Synced Sep 8, 2026, 1:13 PM EDT
Not yet recruiting Not applicable Interventional

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

NCT06816979
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging
Procedure · Device
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting No phase listed Observational

Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer

NCT05081024
View directory record Official record
Conditions
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8, Stage IIC Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8, Stage IIIC Rectal Cancer AJCC v8
Interventions
Biopsy, Biospecimen Collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 8, 2026, 1:13 PM EDT
Completed Phase 1 Interventional

CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy

NCT02693080
View directory record Official record
Conditions
Malignant Lung Neoplasm, Metastatic Malignant Neoplasm in the Lung, Non-Small Cell Lung Carcinoma, Stage IV Lung Cancer
Interventions
CAPP-Seq, Isovue-200, Computed Tomography Perfusion Imaging
Device · Drug · Radiation
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 8, 2026, 1:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

NCT05127096
View directory record Official record
Conditions
Colorectal Cancer Screening
Interventions
FirstSight blood test
Diagnostic Test
Lead sponsor
CellMax Life
Industry
Eligibility
45 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
15
States / cities
Huntsville, Alabama • Chula Vista, California • Lancaster, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 8, 2026, 1:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

PATHFINDER 2: A Multi-Cancer Early Detection Study

NCT05155605
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
Multi-Cancer Early Detection Test
Device
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
50 Years and older
Enrollment
35,883 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
55
States / cities
Auburn, California • Davis, California • Elk Grove, California + 45 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Not listed No phase listed Observational

Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers

NCT04712877
View directory record Official record
Conditions
NSCLC
Interventions
ctDNA, tumor NGS
Diagnostic Test
Lead sponsor
Lung Cancer Mutation Consortium
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
21
States / cities
Davis, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 8, 2026, 1:13 PM EDT
Completed No phase listed Observational

Concordance Between ctDNA Assay and FoundationOne

NCT02620527
View directory record Official record
Conditions
Circulating Tumor DNA, Cancer, Neoplasms, Genomic Testing, Genomic Alterations
Interventions
Not listed
Lead sponsor
Foundation Medicine
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting No phase listed Observational

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

NCT04165798
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tumor Imaging, Tumor Tissue Collection, Blood Sample Collection
Diagnostic Test · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
1,065 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2032
U.S. locations
18
States / cities
Gilbert, Arizona • Duarte, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting No phase listed Observational

Investigating Hereditary Risk In Thoracic Cancers (INHERIT)

NCT05587439
View directory record Official record
Conditions
Lung Cancer, Genetic Disease, Genetic Predisposition, Hereditary Diseases
Interventions
Data and Specimen Collection
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

NCT05770531
View directory record Official record
Conditions
Metastatic HER2-Negative Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT04354064
View directory record Official record
Conditions
Healthy Volunteer, Prostate Cancer, Head and Neck Cancer, Esophageal Cancer, Genitourinary Cancer, Sarcoma, Breast Cancer, Colon Cancer, Gastrointestinal Cancer, Solid Tumor Cancer, Lung Cancer, Skin Cancer, Melanoma
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

NCT06070012
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Tebentafusp
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

NCT07058012
View directory record Official record
Conditions
Colo-rectal Cancer
Interventions
Cemiplimab, cemiplimab plus fianlimab, cemiplimab + REGN7075, ctDNA testing
Drug · Other
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
13
States / cities
Gainesville, Florida • Iowa City, Iowa • Kansas City, Kansas + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Terminated No phase listed Observational

NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial

NCT04698681
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Non-squamous Non-small-cell Lung Cancer, Non-Squamous Non-Small Cell Neoplasm of Lung, KEAP1 Gene Mutation, NRF2 Mutation, NFE2L2 Gene Mutation
Interventions
Not listed
Lead sponsor
Calithera Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
63
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2023 · Synced Sep 8, 2026, 1:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Plasma ctDNA in Patients Undergoing Diagnostic Colonoscopy

NCT02665299
View directory record Official record
Conditions
Colon Cancer, Colon Adenomas, Colon Polyps
Interventions
Not listed
Lead sponsor
Pathway Genomics
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting No phase listed Observational

Metastatic Leiomyosarcoma Biomarker Protocol

NCT05653388
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Plasma Collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Santa Monica, California • Miami, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Phase 2 Interventional

Trial of AMB-05X for Patients With ctDNA(+) Colorectal Cancer After Curative-intent Treatment

NCT06617858
View directory record Official record
Conditions
Colorectal Cancer
Interventions
AMB-05X
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Not applicable Interventional

Circulating Tumor DNA in Stage I, II, and III Germ-Cell Tumors

NCT07401316
View directory record Official record
Conditions
Germ Cell Cancer Metastatic
Interventions
Whole blood for ctDNA
Diagnostic Test
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Not yet recruiting No phase listed Observational

ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer

NCT05629442
View directory record Official record
Conditions
Rectal Cancer, Non Metastatic Rectal Cancer
Interventions
ctDNA
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Suspended Not applicable Interventional

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

NCT04929015
View directory record Official record
Conditions
Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage, Digestive System Neoplasm, Esophageal Carcinoma by AJCC V8 Stage, Gastric Carcinoma by AJCC V8 Stage, Liver and Intrahepatic Bile Duct Carcinoma, Peritoneal Carcinomatosis
Interventions
Biospecimen Collection - blood and tissue sample collection, Electronic Health Record Review
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 8, 2026, 1:13 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

REFLECTION: A Clinical Practice Learning Program for Galleri®

NCT05205967
View directory record Official record
Conditions
Early Detection of Cancer, Cancer
Interventions
MCED, SOC
Other
Lead sponsor
GRAIL, Inc.
Industry
Eligibility
22 Years and older
Enrollment
14,633 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
16
States / cities
Scottsdale, Arizona • Burbank, California • Fullerton, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 8, 2026, 1:13 PM EDT
Not listed No phase listed Observational

Recurrence Monitoring in NSCLC Using Circulating Tumor DNA

NCT03878537
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Scripps Translational Science Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2021 · Synced Sep 8, 2026, 1:13 PM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 8, 2026, 1:13 PM EDT